ID   NT-38
AC   CVCL_C4N9
DR   cancercelllines; CVCL_C4N9
DR   Wikidata; Q116050018
RX   PubMed=36269546;
CC   Doubling time: 5.21 days (PubMed=36269546).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Ser1346Ter (c.4037C>A); ClinVar=VCV001737245; Zygosity=Unspecified (PubMed=36269546).
CC   Sequence variation: Mutation; HGNC; HGNC:9829; RAF1; Simple; p.Ser259Phe (c.776C>T); ClinVar=VCV000040603; Zygosity=Unspecified (PubMed=36269546).
CC   Derived from site: In situ; Small intestine, duodenum; UBERON=UBERON_0002114.
DI   NCIt; C135080; Duodenal neuroendocrine tumor
DI   ORDO; Orphanet_100076; Duodenal neuroendocrine tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   78Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 19-12-24; Version: 5
//
RX   PubMed=36269546; DOI=10.1007/s13402-022-00727-z; PMCID=PMC9747820;
RA   Viol F., Sipos B., Fahl M., Clauditz T.S., Amin T., Kriegs M.,
RA   Nieser M., Izbicki J.R., Huber S., Lohse A.W., Schrader J.;
RT   "Novel preclinical gastroenteropancreatic neuroendocrine neoplasia
RT   models demonstrate the feasibility of mutation-based targeted
RT   therapy.";
RL   Cell. Oncol. (Dordr.) 45:1401-1419(2022).
//